0001127602-23-003986.txt : 20230208
0001127602-23-003986.hdr.sgml : 20230208
20230208160338
ACCESSION NUMBER: 0001127602-23-003986
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230206
FILED AS OF DATE: 20230208
DATE AS OF CHANGE: 20230208
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Halpin Michael
CENTRAL INDEX KEY: 0001778858
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35280
FILM NUMBER: 23599040
MAIL ADDRESS:
STREET 1: C/O VERICEL CORPORATION
STREET 2: 64 SIDNEY ST.
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Vericel Corp
CENTRAL INDEX KEY: 0000887359
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 943096597
STATE OF INCORPORATION: MI
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 64 SIDNEY ST.
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
BUSINESS PHONE: 7349305555
MAIL ADDRESS:
STREET 1: 64 SIDNEY ST.
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
FORMER COMPANY:
FORMER CONFORMED NAME: AASTROM BIOSCIENCES INC
DATE OF NAME CHANGE: 19960428
4
1
form4.xml
PRIMARY DOCUMENT
X0306
4
2023-02-06
0000887359
Vericel Corp
VCEL
0001778858
Halpin Michael
C/O VERICEL CORPORATION
CAMBRIDGE
MA
02139
1
Chief Operating Officer
Common Stock
2023-02-06
4
M
0
1875
0
A
12754
D
Common Stock
2023-02-06
4
F
0
988
30.60
D
11766
D
Restricted Stock Unit
2023-02-06
4
M
0
1875
D
Common Stock
1875
0
D
The shares of common stock were acquired by the Reporting Person as a result of the vesting of Restricted Stock Units (RSUs) granted to the Reporting Person on February 6, 2019.
These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c).
These shares were withheld by the Issuer to satisfy the tax withholding requirements in connection with the vesting of RSUs.
Each RSU represents a contingent right to receive one share of common stock of Vericel Corporation.
No expiration date for this type of award.
The Fair Market Value of the vested derivative securities is $30.60 per share.
/s/ Sean Flynn, as Attorney-in-Fact for Michael Halpin
2023-02-08